Team:Stockholm/Modelling
From 2010.igem.org
(Difference between revisions)
Line 25: | Line 25: | ||
http://www.ncbi.nlm.nih.gov/pubmed/19597765 | http://www.ncbi.nlm.nih.gov/pubmed/19597765 | ||
</s> | </s> | ||
+ | |||
+ | ---- | ||
+ | |||
+ | ==PPI== | ||
+ | |||
+ | ''The most obvious caveat with co-IP data is that a positive result does not imply a direct interaction between two proteins – binding could be mediated by other partners.'' | ||
+ | "Protein interactions: is seeing believing? J. P. Mackay et al. 2007" |
Revision as of 14:01, 28 June 2010
Production Phase
- Suggested Articles
http://www.ncbi.nlm.nih.gov/pubmed/17536514
http://www.ncbi.nlm.nih.gov/pubmed/17571257
http://www.ncbi.nlm.nih.gov/pubmed/19892171
http://www.ncbi.nlm.nih.gov/pubmed/20201800
Hassan: For production phase, there are several cases that we need to take care of. One of interesting subjects is "inclusion bodies". As Johan and Nina said, it is better to study about over expression.
Secretion
http://www.ncbi.nlm.nih.gov/pubmed/15763404
http://www.ncbi.nlm.nih.gov/pubmed/19597765
PPI
The most obvious caveat with co-IP data is that a positive result does not imply a direct interaction between two proteins – binding could be mediated by other partners. "Protein interactions: is seeing believing? J. P. Mackay et al. 2007"